Cite

HARVARD Citation

    Yale, J. et al. (n.d.). Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, obesity & metabolism. 16 (10), pp. 1016-1027. [Online]. 
  
Back to record